Metabolism Drugs Market: By Therapy Type (Enzyme Replacement Therapy, Substrate Reduction Therapy, Small Molecule Drugs, Drug Therapy, Others), By Application (Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism Disease, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

Metabolism Drugs market was valued at USD 7,098.9 million in 2022 and is expected to grow at a 5.42% CAGR from 2023 to 2029. Metabolism is the process of breakdown of food in the body to various proteins, carbohydrates, and fat. The metabolism may be affected due to lack of production of enzymes in the body. Metabolism drugs are used to treat metabolism disease as a result of improper or inadequate or malfunctioning of metabolism process in the body. Metabolism disease can also be caused by epigenetics. The genetically caused metabolism disease has less incidence and prevalence rate. Metabolic diseases include hereditary tyrosinemia, Gaucher disease, hereditary orotic aciduria, and Fabry disease. Increasing prevalence of metabolic disorders, and rising awareness among the public about treatment and diagnosis of various metabolic disorders is expected to drive the growth of metabolic drugs market over the forecasted years. In addition, presence of several risk factors like obesity, presence of comorbidities, and growing unhealthy lifestyle is expected to boost the growth of metabolism drugs market.

Furthermore, increasing development of analytical tools along with research and development of new drugs are expected to trigger the metabolism drugs market growth. For instance, researchers in University Hospitals Cleveland Medical Centre discovered a hormone called asprosin, which stimulates appetite and increases blood glucose levels by acting on the hypothalamus and the liver in human body. However, the side effects caused by the prolonged treatment along with the clinical hold on trails by market players is expected to hinder the market growth of metabolism drugs market over the forecasted years. For instance, in June 2022, Astellas Pharma, Inc. announced that the USFDA has placed a hold on the FORTIS phase1/2 trial following the occurrence of serious adverse effects. Geographically, North America region held the major market share in 2022 and is expected to dominate the global metabolism drugs market in the forecasted years.

Metabolism Drugs Market Key Developments:

• In November 2020, USFDA approves the first drug ‘oxlumo’ to treat rare metabolic disorder-primary hyperoxaluria type 1.